Product news

Share this article:
The FDA has approved Alcon's Patanase (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. Patanase will be available in May, Alcon said. 
 
GlaxoSmithKline and Pozen announced FDA approval of Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet combines a GSK-developed triptan designed to target migraines, with an anti-inflammatory pain reliever in single tablet form.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.